Antiepileptic Drugs Market Drivers [2021-2031]
The Antiepileptic Drugs Market is expected to register a CAGR of 4.7% from 2023 to 2031, with a market size expanding from US$ XX million in 2023 to US$ XX Million by 2031.
The Antiepileptic Drugs Market report covers analysis by Drug Class (First Generation, Second Generation, Third Generation); Distribution Channel (Hospital Pharmacies, Retail Pharmacies) , and Geography (North America, Europe, Asia Pacific, and South and Central America). The global analysis is further broken-down at regional level and major countries. The Report Offers the Value in USD for the above analysis and segments.
Purpose of the ReportThe report Antiepileptic Drugs Market by The Insight Partners aims to describe the present landscape and future growth, top driving factors, challenges, and opportunities. This will provide insights to various business stakeholders, such as:
- Technology Providers/Manufacturers: To understand the evolving market dynamics and know the potential growth opportunities, enabling them to make informed strategic decisions.
- Investors: To conduct a comprehensive trend analysis regarding the market growth rate, market financial projections, and opportunities that exist across the value chain.
- Regulatory bodies: To regulate policies and police activities in the market with the aim of minimizing abuse, preserving investor trust and confidence, and upholding the integrity and stability of the market.
Antiepileptic Drugs Market Segmentation
Drug Class- First Generation
- Second Generation
- Third Generation
- Hospital Pharmacies
- Retail Pharmacies
Strategic Insights
Antiepileptic Drugs Market Growth Drivers- Increasing cases of epilepsy: The global market for antiepileptic drugs expands with increasing cases of epilepsy. Effective therapies targeted at different types of epilepsy drive the market size, which shapes the market trends.
- Government Support: Supportive policies for the management of neurological disorders are conducive to the development of antiepileptic drugs. Market trends indicate this as an essential factor in maintaining market size and growth.
- Growing Awareness and Early Diagnosis:
Rising awareness of epilepsy and improved diagnostic tools are leading to earlier detection, which helps in initiating timely treatment and increases the demand for AEDs.
- Aging Population:
The aging global population, which is more prone to neurological disorders, is contributing to an increased number of elderly individuals being diagnosed with epilepsy, thereby increasing the need for AEDs.
- Personalized Medicine in Epilepsy Treatment:
The trend toward personalized medicine, where treatment is tailored to the patient's genetic profile and specific type of epilepsy, is helping optimize AED therapy for better outcomes.
- Combination Therapy:
The use of combination therapies, where patients receive multiple AEDs to manage complex or resistant forms of epilepsy, is on the rise. This approach helps control seizures in patients who do not respond well to single-drug therapy.
- Injectable and Long-Acting Formulations:
The development of injectable AEDs and long-acting formulations is improving patient adherence and reducing the frequency of dosing, which is a key trend in the market.
- Pipeline Drugs and Novel Therapies:
The pipeline for AEDs is rich with promising drugs that are expected to address treatment-resistant epilepsy, a significant unmet need. Novel therapies, including gene therapies and neurostimulation devices, are expected to offer new treatment options.
- Increasing Focus on Pediatric Epilepsy:
Growing recognition of the unique challenges in treating pediatric epilepsy is driving the development of specialized AEDs for children. This represents an important market segment with significant opportunities.
- Strategic Partnerships and Collaborations:
Collaborations between pharmaceutical companies, research institutions, and healthcare providers are expected to accelerate the development and commercialization of new AED therapies, fostering market growth.
Market Report Scope
Key Selling Points
- Comprehensive Coverage: The report comprehensively covers the analysis of products, services, types, and end users of the Antiepileptic Drugs Market, providing a holistic landscape.
- Expert Analysis: The report is compiled based on the in-depth understanding of industry experts and analysts.
- Up-to-date Information: The report assures business relevance due to its coverage of recent information and data trends.
- Customization Options: This report can be customized to cater to specific client requirements and suit the business strategies aptly.
The research report on the Antiepileptic Drugs Market can, therefore, help spearhead the trail of decoding and understanding the industry scenario and growth prospects. Although there can be a few valid concerns, the overall benefits of this report tend to outweigh the disadvantages.
REGIONAL FRAMEWORK
Have a question?
Mrinal
Mrinal will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.
Speak to Analyst
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
This text is related
to segments covered.
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
This text is related
to country scope.
Frequently Asked Questions
The Antiepileptic Drugs Market is estimated to witness a CAGR of 4.7% from 2023 to 2031.
The major factors driving the market are: Rising epilepsy prevalence, Innovation in drug formulations, Government initiatives and funding
Key future trends in this market are - New Drug Approvals, Pediatric Epilepsy Treatments, Generic Drug Availability
Key companies of this market are: GlaxoSmithKline Plc, Johnson & Johnson Services, Inc., Abbott, Bausch Health Companies Inc., Pfizer, Inc., Sunovion Pharmaceuticals Inc., Novartis AG, UCB S.A., Eisai Co., Ltd., Otsuka Holdings Co., Ltd.
The report can be delivered in PDF/PPT format; we can also share excel dataset based on the request.
Some of the customization options available based on request are additional 3-5 company profiles and country-specific analysis of 3-5 countries of your choice. Customizations are to be requested/discussed before making final order confirmation, as our team would review the same and check the feasibility.
1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Antiepileptic Drugs Market - By Drug Class
1.3.2 Antiepileptic Drugs Market - By Distribution Channel
1.3.3 Antiepileptic Drugs Market - By Region
1.3.3.1 By Country
2. KEY TAKEWAYS
3. RESEARCH METHODOLOGY
4. ANTIEPILEPTIC DRUGS MARKET LANDSCAPE
4.1. OVERVIEW
4.2. PEST ANALYSIS
4.2.1 North America - Pest Analysis
4.2.2 Europe - Pest Analysis
4.2.3 Asia-Pacific - Pest Analysis
4.2.4 Middle East and Africa - Pest Analysis
4.2.5 South and Central America - Pest Analysis
4.3. EXPERT OPINIONS
5. ANTIEPILEPTIC DRUGS MARKET - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS, RESTRAINTS & EXPECTED INFLUENCE OF COVID-19 PANDEMIC
6. ANTIEPILEPTIC DRUGS MARKET - GLOBAL MARKET ANALYSIS
6.1. ANTIEPILEPTIC DRUGS - GLOBAL MARKET OVERVIEW
6.2. ANTIEPILEPTIC DRUGS - GLOBAL MARKET AND FORECAST TO 2028
6.3. MARKET POSITIONING/MARKET SHARE
7. ANTIEPILEPTIC DRUGS MARKET - REVENUE AND FORECASTS TO 2028 - DRUG CLASS
7.1. OVERVIEW
7.2. DRUG CLASS MARKET FORECASTS AND ANALYSIS
7.3. FIRST GENERATION
7.3.1. Overview
7.3.2. First Generation Market Forecast and Analysis
7.4. SECOND GENERATION
7.4.1. Overview
7.4.2. Second Generation Market Forecast and Analysis
7.5. THIRD GENERATION
7.5.1. Overview
7.5.2. Third Generation Market Forecast and Analysis
8. ANTIEPILEPTIC DRUGS MARKET - REVENUE AND FORECASTS TO 2028 - DISTRIBUTION CHANNEL
8.1. OVERVIEW
8.2. DISTRIBUTION CHANNEL MARKET FORECASTS AND ANALYSIS
8.3. HOSPITAL PHARMACIES
8.3.1. Overview
8.3.2. Hospital Pharmacies Market Forecast and Analysis
8.4. RETAIL PHARMACIES
8.4.1. Overview
8.4.2. Retail Pharmacies Market Forecast and Analysis
9. ANTIEPILEPTIC DRUGS MARKET REVENUE AND FORECASTS TO 2028 - GEOGRAPHICAL ANALYSIS
9.1. NORTH AMERICA
9.1.1 North America Antiepileptic Drugs Market Overview
9.1.2 North America Antiepileptic Drugs Market Forecasts and Analysis
9.1.3 North America Antiepileptic Drugs Market Forecasts and Analysis - By Drug Class
9.1.4 North America Antiepileptic Drugs Market Forecasts and Analysis - By Distribution Channel
9.1.5 North America Antiepileptic Drugs Market Forecasts and Analysis - By Countries
9.1.5.1 United States Antiepileptic Drugs Market
9.1.5.1.1 United States Antiepileptic Drugs Market by Drug Class
9.1.5.1.2 United States Antiepileptic Drugs Market by Distribution Channel
9.1.5.2 Canada Antiepileptic Drugs Market
9.1.5.2.1 Canada Antiepileptic Drugs Market by Drug Class
9.1.5.2.2 Canada Antiepileptic Drugs Market by Distribution Channel
9.1.5.3 Mexico Antiepileptic Drugs Market
9.1.5.3.1 Mexico Antiepileptic Drugs Market by Drug Class
9.1.5.3.2 Mexico Antiepileptic Drugs Market by Distribution Channel
9.2. EUROPE
9.2.1 Europe Antiepileptic Drugs Market Overview
9.2.2 Europe Antiepileptic Drugs Market Forecasts and Analysis
9.2.3 Europe Antiepileptic Drugs Market Forecasts and Analysis - By Drug Class
9.2.4 Europe Antiepileptic Drugs Market Forecasts and Analysis - By Distribution Channel
9.2.5 Europe Antiepileptic Drugs Market Forecasts and Analysis - By Countries
9.2.5.1 Germany Antiepileptic Drugs Market
9.2.5.1.1 Germany Antiepileptic Drugs Market by Drug Class
9.2.5.1.2 Germany Antiepileptic Drugs Market by Distribution Channel
9.2.5.2 France Antiepileptic Drugs Market
9.2.5.2.1 France Antiepileptic Drugs Market by Drug Class
9.2.5.2.2 France Antiepileptic Drugs Market by Distribution Channel
9.2.5.3 Italy Antiepileptic Drugs Market
9.2.5.3.1 Italy Antiepileptic Drugs Market by Drug Class
9.2.5.3.2 Italy Antiepileptic Drugs Market by Distribution Channel
9.2.5.4 Spain Antiepileptic Drugs Market
9.2.5.4.1 Spain Antiepileptic Drugs Market by Drug Class
9.2.5.4.2 Spain Antiepileptic Drugs Market by Distribution Channel
9.2.5.5 United Kingdom Antiepileptic Drugs Market
9.2.5.5.1 United Kingdom Antiepileptic Drugs Market by Drug Class
9.2.5.5.2 United Kingdom Antiepileptic Drugs Market by Distribution Channel
9.3. ASIA-PACIFIC
9.3.1 Asia-Pacific Antiepileptic Drugs Market Overview
9.3.2 Asia-Pacific Antiepileptic Drugs Market Forecasts and Analysis
9.3.3 Asia-Pacific Antiepileptic Drugs Market Forecasts and Analysis - By Drug Class
9.3.4 Asia-Pacific Antiepileptic Drugs Market Forecasts and Analysis - By Distribution Channel
9.3.5 Asia-Pacific Antiepileptic Drugs Market Forecasts and Analysis - By Countries
9.3.5.1 Australia Antiepileptic Drugs Market
9.3.5.1.1 Australia Antiepileptic Drugs Market by Drug Class
9.3.5.1.2 Australia Antiepileptic Drugs Market by Distribution Channel
9.3.5.2 China Antiepileptic Drugs Market
9.3.5.2.1 China Antiepileptic Drugs Market by Drug Class
9.3.5.2.2 China Antiepileptic Drugs Market by Distribution Channel
9.3.5.3 India Antiepileptic Drugs Market
9.3.5.3.1 India Antiepileptic Drugs Market by Drug Class
9.3.5.3.2 India Antiepileptic Drugs Market by Distribution Channel
9.3.5.4 Japan Antiepileptic Drugs Market
9.3.5.4.1 Japan Antiepileptic Drugs Market by Drug Class
9.3.5.4.2 Japan Antiepileptic Drugs Market by Distribution Channel
9.3.5.5 South Korea Antiepileptic Drugs Market
9.3.5.5.1 South Korea Antiepileptic Drugs Market by Drug Class
9.3.5.5.2 South Korea Antiepileptic Drugs Market by Distribution Channel
9.4. MIDDLE EAST AND AFRICA
9.4.1 Middle East and Africa Antiepileptic Drugs Market Overview
9.4.2 Middle East and Africa Antiepileptic Drugs Market Forecasts and Analysis
9.4.3 Middle East and Africa Antiepileptic Drugs Market Forecasts and Analysis - By Drug Class
9.4.4 Middle East and Africa Antiepileptic Drugs Market Forecasts and Analysis - By Distribution Channel
9.4.5 Middle East and Africa Antiepileptic Drugs Market Forecasts and Analysis - By Countries
9.4.5.1 South Africa Antiepileptic Drugs Market
9.4.5.1.1 South Africa Antiepileptic Drugs Market by Drug Class
9.4.5.1.2 South Africa Antiepileptic Drugs Market by Distribution Channel
9.4.5.2 Saudi Arabia Antiepileptic Drugs Market
9.4.5.2.1 Saudi Arabia Antiepileptic Drugs Market by Drug Class
9.4.5.2.2 Saudi Arabia Antiepileptic Drugs Market by Distribution Channel
9.4.5.3 U.A.E Antiepileptic Drugs Market
9.4.5.3.1 U.A.E Antiepileptic Drugs Market by Drug Class
9.4.5.3.2 U.A.E Antiepileptic Drugs Market by Distribution Channel
9.5. SOUTH AND CENTRAL AMERICA
9.5.1 South and Central America Antiepileptic Drugs Market Overview
9.5.2 South and Central America Antiepileptic Drugs Market Forecasts and Analysis
9.5.3 South and Central America Antiepileptic Drugs Market Forecasts and Analysis - By Drug Class
9.5.4 South and Central America Antiepileptic Drugs Market Forecasts and Analysis - By Distribution Channel
9.5.5 South and Central America Antiepileptic Drugs Market Forecasts and Analysis - By Countries
9.5.5.1 Brazil Antiepileptic Drugs Market
9.5.5.1.1 Brazil Antiepileptic Drugs Market by Drug Class
9.5.5.1.2 Brazil Antiepileptic Drugs Market by Distribution Channel
9.5.5.2 Argentina Antiepileptic Drugs Market
9.5.5.2.1 Argentina Antiepileptic Drugs Market by Drug Class
9.5.5.2.2 Argentina Antiepileptic Drugs Market by Distribution Channel
10. INDUSTRY LANDSCAPE
10.1. MERGERS AND ACQUISITIONS
10.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
10.3. NEW PRODUCT LAUNCHES
10.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS
11. ANTIEPILEPTIC DRUGS MARKET, KEY COMPANY PROFILES
11.1. GLAXOSMITHKLINE PLC
11.1.1. Key Facts
11.1.2. Business Description
11.1.3. Products and Services
11.1.4. Financial Overview
11.1.5. SWOT Analysis
11.1.6. Key Developments
11.2. JOHNSON & JOHNSON SERVICES, INC.
11.2.1. Key Facts
11.2.2. Business Description
11.2.3. Products and Services
11.2.4. Financial Overview
11.2.5. SWOT Analysis
11.2.6. Key Developments
11.3. ABBOTT
11.3.1. Key Facts
11.3.2. Business Description
11.3.3. Products and Services
11.3.4. Financial Overview
11.3.5. SWOT Analysis
11.3.6. Key Developments
11.4. BAUSCH HEALTH COMPANIES INC.
11.4.1. Key Facts
11.4.2. Business Description
11.4.3. Products and Services
11.4.4. Financial Overview
11.4.5. SWOT Analysis
11.4.6. Key Developments
11.5. PFIZER, INC.
11.5.1. Key Facts
11.5.2. Business Description
11.5.3. Products and Services
11.5.4. Financial Overview
11.5.5. SWOT Analysis
11.5.6. Key Developments
11.6. SUNOVION PHARMACEUTICALS INC.
11.6.1. Key Facts
11.6.2. Business Description
11.6.3. Products and Services
11.6.4. Financial Overview
11.6.5. SWOT Analysis
11.6.6. Key Developments
11.7. NOVARTIS AG
11.7.1. Key Facts
11.7.2. Business Description
11.7.3. Products and Services
11.7.4. Financial Overview
11.7.5. SWOT Analysis
11.7.6. Key Developments
11.8. UCB S.A.
11.8.1. Key Facts
11.8.2. Business Description
11.8.3. Products and Services
11.8.4. Financial Overview
11.8.5. SWOT Analysis
11.8.6. Key Developments
11.9. EISAI CO., LTD.
11.9.1. Key Facts
11.9.2. Business Description
11.9.3. Products and Services
11.9.4. Financial Overview
11.9.5. SWOT Analysis
11.9.6. Key Developments
11.10. OTSUKA HOLDINGS CO., LTD.
11.10.1. Key Facts
11.10.2. Business Description
11.10.3. Products and Services
11.10.4. Financial Overview
11.10.5. SWOT Analysis
11.10.6. Key Developments
12. APPENDIX
12.1. ABOUT THE INSIGHT PARTNERS
12.2. GLOSSARY OF TERMS
1. GlaxoSmithKline Plc
2. Johnson & Johnson Services, Inc.
3. Abbott
4. Bausch Health Companies Inc.
5. Pfizer, Inc.
6. Sunovion Pharmaceuticals Inc.
7. Novartis AG
8. UCB S. A.
9. Eisai Co. , Ltd.
10. Otsuka Holdings Co. , Ltd.
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published many reports and advised several clients across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organizations are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in the last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/Sales Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- 3.1 Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- 3.2 Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- 3.3 Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- 3.4 Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.
Get Free Sample For